And anavex failed every single patient scoring under 20. That has not been established for SAVA but HAS for anavex who is NO LONGER seeking that demographic .
If you honestly think sava isn't increasing test scores in patients scoring 16 to 20 then you have to admit patient with mmse >20 must be doing a heck of a lot better than anybody else. You can't have it both ways.
Market Data 
Markets 
